APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pet Biopharmaceuticals

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Pet Biopharmaceuticals Market Analysis and Forecast 2026-2032

30 December 2025195 pages

Choose your research edition.

Industry ResearchPet Biopharmaceuticals Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Pet Biopharmaceuticals Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Pet Biopharmaceuticals Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pet Biopharmaceuticals Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Pet Biopharmaceuticals Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Pet Biopharmaceuticals market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Pet Biopharmaceuticals is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Pet Biopharmaceuticals is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Pet Biopharmaceuticals is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Pet Biopharmaceuticals is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Pet Biopharmaceuticals include Merck, Zoetis, Virbac, Vetoquinol, Ouro Fino Saude, Norbrook, Jindun, Elanco and Dechra Veterinary Products, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Pet Biopharmaceuticals, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Pet Biopharmaceuticals, also provides the revenue of main regions and countries. Of the upcoming market potential for Pet Biopharmaceuticals, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Pet Biopharmaceuticals revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Pet Biopharmaceuticals market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Pet Biopharmaceuticals revenue, projected growth trends, production technology, application and end-user industry.

Pet Biopharmaceuticals Segment by Company

Merck

Zoetis

Virbac

Vetoquinol

Ouro Fino Saude

Norbrook

Jindun

Elanco

Dechra Veterinary Products

Chopperlvya Animal Health

Ceva

CAHIC

Boehringer Ingelheim

Pet Biopharmaceuticals Segment by Type

Antiparasitic

Antibacterial

Biological Products

Others

Pet Biopharmaceuticals Segment by Application

Prevention

Treatment

Pet Biopharmaceuticals Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pet Biopharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pet Biopharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pet Biopharmaceuticals.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Pet Biopharmaceuticals in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Pet Biopharmaceuticals company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pet Biopharmaceuticals revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Pet Biopharmaceuticals Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Antiparasitic Major Player Table 3. Antibacterial Major Player Table 4. Biological Products Major Player Table 5. Others Major Player Table 6. Global Pet Biopharmaceuticals Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Prevention Major Player Table 8. Treatment Major Player Table 9. Pet Biopharmaceuticals Industry Trends Table 10. Pet Biopharmaceuticals Industry Drivers Table 11. Pet Biopharmaceuticals Industry Opportunities and Challenges Table 12. Pet Biopharmaceuticals Industry Restraints Table 13. Global Pet Biopharmaceuticals Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Pet Biopharmaceuticals Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Pet Biopharmaceuticals Market Share by Region (2021-2026) Table 16. Global Pet Biopharmaceuticals Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Pet Biopharmaceuticals Market Share by Region (2027-2032) Table 18. Global Pet Biopharmaceuticals Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Pet Biopharmaceuticals Revenue Market Share by Players (2021-2026) Table 20. Global Pet Biopharmaceuticals Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Pet Biopharmaceuticals Key Players Headquarters & Area Served Table 22. Global Pet Biopharmaceuticals Players, Product Type & Application Table 23. Global Pet Biopharmaceuticals Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Pet Biopharmaceuticals by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Pet Biopharmaceuticals Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Pet Biopharmaceuticals Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Pet Biopharmaceuticals Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Pet Biopharmaceuticals Revenue Market Share by Type (2021-2026) Table 30. Global Pet Biopharmaceuticals Revenue Market Share by Type (2027-2032) Table 31. Global Pet Biopharmaceuticals Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Pet Biopharmaceuticals Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Pet Biopharmaceuticals Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Pet Biopharmaceuticals Revenue Market Share by Application (2021-2026) Table 35. Global Pet Biopharmaceuticals Revenue Market Share by Application (2027-2032) Table 36. Merck Company Information Table 37. Merck Business Overview Table 38. Merck Pet Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Merck Pet Biopharmaceuticals Product Portfolio Table 40. Merck Recent Development Table 41. Zoetis Company Information Table 42. Zoetis Business Overview Table 43. Zoetis Pet Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Zoetis Pet Biopharmaceuticals Product Portfolio Table 45. Zoetis Recent Development Table 46. Virbac Company Information Table 47. Virbac Business Overview Table 48. Virbac Pet Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Virbac Pet Biopharmaceuticals Product Portfolio Table 50. Virbac Recent Development Table 51. Vetoquinol Company Information Table 52. Vetoquinol Business Overview Table 53. Vetoquinol Pet Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Vetoquinol Pet Biopharmaceuticals Product Portfolio Table 55. Vetoquinol Recent Development Table 56. Ouro Fino Saude Company Information Table 57. Ouro Fino Saude Business Overview Table 58. Ouro Fino Saude Pet Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Ouro Fino Saude Pet Biopharmaceuticals Product Portfolio Table 60. Ouro Fino Saude Recent Development Table 61. Norbrook Company Information Table 62. Norbrook Business Overview Table 63. Norbrook Pet Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Norbrook Pet Biopharmaceuticals Product Portfolio Table 65. Norbrook Recent Development Table 66. Jindun Company Information Table 67. Jindun Business Overview Table 68. Jindun Pet Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Jindun Pet Biopharmaceuticals Product Portfolio Table 70. Jindun Recent Development Table 71. Elanco Company Information Table 72. Elanco Business Overview Table 73. Elanco Pet Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Elanco Pet Biopharmaceuticals Product Portfolio Table 75. Elanco Recent Development Table 76. Dechra Veterinary Products Company Information Table 77. Dechra Veterinary Products Business Overview Table 78. Dechra Veterinary Products Pet Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Dechra Veterinary Products Pet Biopharmaceuticals Product Portfolio Table 80. Dechra Veterinary Products Recent Development Table 81. Chopperlvya Animal Health Company Information Table 82. Chopperlvya Animal Health Business Overview Table 83. Chopperlvya Animal Health Pet Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Chopperlvya Animal Health Pet Biopharmaceuticals Product Portfolio Table 85. Chopperlvya Animal Health Recent Development Table 86. Ceva Company Information Table 87. Ceva Business Overview Table 88. Ceva Pet Biopharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Ceva Pet Biopharmaceuticals Product Portfolio Table 90. Ceva Recent Development Table 91. CAHIC Company Information Table 92. CAHIC Business Overview Table 93. CAHIC Pet Biopharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. CAHIC Pet Biopharmaceuticals Product Portfolio Table 95. CAHIC Recent Development Table 96. Boehringer Ingelheim Company Information Table 97. Boehringer Ingelheim Business Overview Table 98. Boehringer Ingelheim Pet Biopharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Boehringer Ingelheim Pet Biopharmaceuticals Product Portfolio Table 100. Boehringer Ingelheim Recent Development Table 101. North America Pet Biopharmaceuticals Revenue by Type (2021-2026) & (US$ Million) Table 102. North America Pet Biopharmaceuticals Revenue by Type (2027-2032) & (US$ Million) Table 103. North America Pet Biopharmaceuticals Revenue by Application (2021-2026) & (US$ Million) Table 104. North America Pet Biopharmaceuticals Revenue by Application (2027-2032) & (US$ Million) Table 105. North America Pet Biopharmaceuticals Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 106. North America Pet Biopharmaceuticals Revenue by Country (2021-2026) & (US$ Million) Table 107. North America Pet Biopharmaceuticals Revenue by Country (US$ Million) & (2027-2032) Table 108. Europe Pet Biopharmaceuticals Revenue by Type (2021-2026) & (US$ Million) Table 109. Europe Pet Biopharmaceuticals Revenue by Type (2027-2032) & (US$ Million) Table 110. Europe Pet Biopharmaceuticals Revenue by Application (2021-2026) & (US$ Million) Table 111. Europe Pet Biopharmaceuticals Revenue by Application (2027-2032) & (US$ Million) Table 112. Europe Pet Biopharmaceuticals Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 113. Europe Pet Biopharmaceuticals Revenue by Country (2021-2026) & (US$ Million) Table 114. Europe Pet Biopharmaceuticals Revenue by Country (US$ Million) & (2027-2032) Table 115. China Pet Biopharmaceuticals Revenue by Type (2021-2026) & (US$ Million) Table 116. China Pet Biopharmaceuticals Revenue by Type (2027-2032) & (US$ Million) Table 117. China Pet Biopharmaceuticals Revenue by Application (2021-2026) & (US$ Million) Table 118. China Pet Biopharmaceuticals Revenue by Application (2027-2032) & (US$ Million) Table 119. Asia Pet Biopharmaceuticals Revenue by Type (2021-2026) & (US$ Million) Table 120. Asia Pet Biopharmaceuticals Revenue by Type (2027-2032) & (US$ Million) Table 121. Asia Pet Biopharmaceuticals Revenue by Application (2021-2026) & (US$ Million) Table 122. Asia Pet Biopharmaceuticals Revenue by Application (2027-2032) & (US$ Million) Table 123. Asia Pet Biopharmaceuticals Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 124. Asia Pet Biopharmaceuticals Revenue by Region (US$ Million) & (2021-2026) Table 125. Asia Pet Biopharmaceuticals Revenue by Region (US$ Million) & (2027-2032) Table 126. SAMEA Pet Biopharmaceuticals Revenue by Type (2021-2026) & (US$ Million) Table 127. SAMEA Pet Biopharmaceuticals Revenue by Type (2027-2032) & (US$ Million) Table 128. SAMEA Pet Biopharmaceuticals Revenue by Application (2021-2026) & (US$ Million) Table 129. SAMEA Pet Biopharmaceuticals Revenue by Application (2027-2032) & (US$ Million) Table 130. SAMEA Pet Biopharmaceuticals Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 131. SAMEA Pet Biopharmaceuticals Revenue by Country (2021-2026) & (US$ Million) Table 132. SAMEA Pet Biopharmaceuticals Revenue by Country (US$ Million) & (2027-2032) Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources Table 136. Primary Sources List of Figures Figure 1. Pet Biopharmaceuticals Image Figure 2. Global Pet Biopharmaceuticals Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pet Biopharmaceuticals Market Size Share 2021 VS 2025 VS 2032 Figure 4. Antiparasitic Image Figure 5. Antibacterial Image Figure 6. Biological Products Image Figure 7. Others Image Figure 8. Global Pet Biopharmaceuticals Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Pet Biopharmaceuticals Market Size Share 2021 VS 2025 VS 2032 Figure 10. Prevention Image Figure 11. Treatment Image Figure 12. Global Pet Biopharmaceuticals Market Size (US$ Million) & (2021-2032) Figure 13. Global Pet Biopharmaceuticals Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Pet Biopharmaceuticals Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Pet Biopharmaceuticals Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Pet Biopharmaceuticals Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Pet Biopharmaceuticals Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Pet Biopharmaceuticals Revenue Market Share by Type (2021-2032) Figure 20. Global Pet Biopharmaceuticals Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Pet Biopharmaceuticals Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Pet Biopharmaceuticals Revenue Market Share by Application (2021-2032) Figure 23. North America Pet Biopharmaceuticals Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Pet Biopharmaceuticals Revenue Share by Type (2021-2032) Figure 25. North America Pet Biopharmaceuticals Revenue Share by Application (2021-2032) Figure 26. North America Pet Biopharmaceuticals Revenue Share by Country (2021-2032) Figure 27. United States Pet Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Pet Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Pet Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Pet Biopharmaceuticals Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Pet Biopharmaceuticals Revenue Share by Type (2021-2032) Figure 32. Europe Pet Biopharmaceuticals Revenue Share by Application (2021-2032) Figure 33. Europe Pet Biopharmaceuticals Revenue Share by Country (2021-2032) Figure 34. Germany Pet Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Pet Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Pet Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Pet Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Pet Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Pet Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Pet Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Pet Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Pet Biopharmaceuticals Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Pet Biopharmaceuticals Revenue Share by Type (2021-2032) Figure 44. China Pet Biopharmaceuticals Revenue Share by Application (2021-2032) Figure 45. Asia Pet Biopharmaceuticals Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Pet Biopharmaceuticals Revenue Share by Type (2021-2032) Figure 47. Asia Pet Biopharmaceuticals Revenue Share by Application (2021-2032) Figure 48. Asia Pet Biopharmaceuticals Revenue Share by Region (2021-2032) Figure 49. Japan Pet Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Pet Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Pet Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Pet Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Pet Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Pet Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Pet Biopharmaceuticals Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Pet Biopharmaceuticals Revenue Share by Type (2021-2032) Figure 57. SAMEA Pet Biopharmaceuticals Revenue Share by Application (2021-2032) Figure 58. SAMEA Pet Biopharmaceuticals Revenue Share by Country (2021-2032) Figure 59. Brazil Pet Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Pet Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Pet Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Pet Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Pet Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Pet Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Pet Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Pet Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Pet Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Pet Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Pet Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Antiparasitic
  • Antibacterial
  • Biological Products
  • Others
Applications
  • Prevention
  • Treatment
Companies covered
  • Merck
  • Zoetis
  • Virbac
  • Vetoquinol
  • Ouro Fino Saude
  • Norbrook
  • Jindun
  • Elanco
  • Dechra Veterinary Products
  • Chopperlvya Animal Health
  • Ceva
  • CAHIC
  • Boehringer Ingelheim

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Pet Biopharmaceuticals Market by Type
  3. 1.2.1 Global Pet Biopharmaceuticals Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Antiparasitic
  5. 1.2.3 Antibacterial
  6. 1.2.4 Biological Products
  7. 1.2.5 Others
  8. 1.3 Pet Biopharmaceuticals Market by Application
  9. 1.3.1 Global Pet Biopharmaceuticals Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Prevention
  11. 1.3.3 Treatment
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Pet Biopharmaceuticals Market Dynamics
  1. 2.1 Pet Biopharmaceuticals Industry Trends
  2. 2.2 Pet Biopharmaceuticals Industry Drivers
  3. 2.3 Pet Biopharmaceuticals Industry Opportunities and Challenges
  4. 2.4 Pet Biopharmaceuticals Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Pet Biopharmaceuticals Market Perspective (2021-2032)
  2. 3.2 Global Pet Biopharmaceuticals Growth Trends by Region
  3. 3.2.1 Global Pet Biopharmaceuticals Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Pet Biopharmaceuticals Market Size by Region (2021-2026)
  5. 3.2.3 Global Pet Biopharmaceuticals Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Pet Biopharmaceuticals Revenue by Players
  2. 4.1.1 Global Pet Biopharmaceuticals Revenue by Players (2021-2026)
  3. 4.1.2 Global Pet Biopharmaceuticals Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Pet Biopharmaceuticals Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Pet Biopharmaceuticals Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Pet Biopharmaceuticals Key Players Headquarters & Area Served
  7. 4.4 Global Pet Biopharmaceuticals Players, Product Type & Application
  8. 4.5 Global Pet Biopharmaceuticals Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Pet Biopharmaceuticals Market CR5 and HHI
  11. 4.6.3 2025 Pet Biopharmaceuticals Tier 1, Tier 2, and Tier 3
5 Pet Biopharmaceuticals Market Size by Type
  1. 5.1 Global Pet Biopharmaceuticals Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Pet Biopharmaceuticals Revenue by Type (2021-2032)
  3. 5.3 Global Pet Biopharmaceuticals Revenue Market Share by Type (2021-2032)
6 Pet Biopharmaceuticals Market Size by Application
  1. 6.1 Global Pet Biopharmaceuticals Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Pet Biopharmaceuticals Revenue by Application (2021-2032)
  3. 6.3 Global Pet Biopharmaceuticals Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Merck
  2. 7.1.1 Merck Company Information
  3. 7.1.2 Merck Business Overview
  4. 7.1.3 Merck Pet Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Merck Pet Biopharmaceuticals Product Portfolio
  6. 7.1.5 Merck Recent Developments
  7. 7.2 Zoetis
  8. 7.2.1 Zoetis Company Information
  9. 7.2.2 Zoetis Business Overview
  10. 7.2.3 Zoetis Pet Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Zoetis Pet Biopharmaceuticals Product Portfolio
  12. 7.2.5 Zoetis Recent Developments
  13. 7.3 Virbac
  14. 7.3.1 Virbac Company Information
  15. 7.3.2 Virbac Business Overview
  16. 7.3.3 Virbac Pet Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Virbac Pet Biopharmaceuticals Product Portfolio
  18. 7.3.5 Virbac Recent Developments
  19. 7.4 Vetoquinol
  20. 7.4.1 Vetoquinol Company Information
  21. 7.4.2 Vetoquinol Business Overview
  22. 7.4.3 Vetoquinol Pet Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Vetoquinol Pet Biopharmaceuticals Product Portfolio
  24. 7.4.5 Vetoquinol Recent Developments
  25. 7.5 Ouro Fino Saude
  26. 7.5.1 Ouro Fino Saude Company Information
  27. 7.5.2 Ouro Fino Saude Business Overview
  28. 7.5.3 Ouro Fino Saude Pet Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Ouro Fino Saude Pet Biopharmaceuticals Product Portfolio
  30. 7.5.5 Ouro Fino Saude Recent Developments
  31. 7.6 Norbrook
  32. 7.6.1 Norbrook Company Information
  33. 7.6.2 Norbrook Business Overview
  34. 7.6.3 Norbrook Pet Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Norbrook Pet Biopharmaceuticals Product Portfolio
  36. 7.6.5 Norbrook Recent Developments
  37. 7.7 Jindun
  38. 7.7.1 Jindun Company Information
  39. 7.7.2 Jindun Business Overview
  40. 7.7.3 Jindun Pet Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Jindun Pet Biopharmaceuticals Product Portfolio
  42. 7.7.5 Jindun Recent Developments
  43. 7.8 Elanco
  44. 7.8.1 Elanco Company Information
  45. 7.8.2 Elanco Business Overview
  46. 7.8.3 Elanco Pet Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Elanco Pet Biopharmaceuticals Product Portfolio
  48. 7.8.5 Elanco Recent Developments
  49. 7.9 Dechra Veterinary Products
  50. 7.9.1 Dechra Veterinary Products Company Information
  51. 7.9.2 Dechra Veterinary Products Business Overview
  52. 7.9.3 Dechra Veterinary Products Pet Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Dechra Veterinary Products Pet Biopharmaceuticals Product Portfolio
  54. 7.9.5 Dechra Veterinary Products Recent Developments
  55. 7.10 Chopperlvya Animal Health
  56. 7.10.1 Chopperlvya Animal Health Company Information
  57. 7.10.2 Chopperlvya Animal Health Business Overview
  58. 7.10.3 Chopperlvya Animal Health Pet Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Chopperlvya Animal Health Pet Biopharmaceuticals Product Portfolio
  60. 7.10.5 Chopperlvya Animal Health Recent Developments
  61. 7.11 Ceva
  62. 7.11.1 Ceva Company Information
  63. 7.11.2 Ceva Business Overview
  64. 7.11.3 Ceva Pet Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Ceva Pet Biopharmaceuticals Product Portfolio
  66. 7.11.5 Ceva Recent Developments
  67. 7.12 CAHIC
  68. 7.12.1 CAHIC Company Information
  69. 7.12.2 CAHIC Business Overview
  70. 7.12.3 CAHIC Pet Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  71. 7.12.4 CAHIC Pet Biopharmaceuticals Product Portfolio
  72. 7.12.5 CAHIC Recent Developments
  73. 7.13 Boehringer Ingelheim
  74. 7.13.1 Boehringer Ingelheim Company Information
  75. 7.13.2 Boehringer Ingelheim Business Overview
  76. 7.13.3 Boehringer Ingelheim Pet Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Boehringer Ingelheim Pet Biopharmaceuticals Product Portfolio
  78. 7.13.5 Boehringer Ingelheim Recent Developments
8 North America
  1. 8.1 North America Pet Biopharmaceuticals Revenue (2021-2032)
  2. 8.2 North America Pet Biopharmaceuticals Revenue by Type (2021-2032)
  3. 8.2.1 North America Pet Biopharmaceuticals Revenue by Type (2021-2026)
  4. 8.2.2 North America Pet Biopharmaceuticals Revenue by Type (2027-2032)
  5. 8.3 North America Pet Biopharmaceuticals Revenue Share by Type (2021-2032)
  6. 8.4 North America Pet Biopharmaceuticals Revenue by Application (2021-2032)
  7. 8.4.1 North America Pet Biopharmaceuticals Revenue by Application (2021-2026)
  8. 8.4.2 North America Pet Biopharmaceuticals Revenue by Application (2027-2032)
  9. 8.5 North America Pet Biopharmaceuticals Revenue Share by Application (2021-2032)
  10. 8.6 North America Pet Biopharmaceuticals Revenue by Country
  11. 8.6.1 North America Pet Biopharmaceuticals Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Pet Biopharmaceuticals Revenue by Country (2021-2026)
  13. 8.6.3 North America Pet Biopharmaceuticals Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Pet Biopharmaceuticals Revenue (2021-2032)
  2. 9.2 Europe Pet Biopharmaceuticals Revenue by Type (2021-2032)
  3. 9.2.1 Europe Pet Biopharmaceuticals Revenue by Type (2021-2026)
  4. 9.2.2 Europe Pet Biopharmaceuticals Revenue by Type (2027-2032)
  5. 9.3 Europe Pet Biopharmaceuticals Revenue Share by Type (2021-2032)
  6. 9.4 Europe Pet Biopharmaceuticals Revenue by Application (2021-2032)
  7. 9.4.1 Europe Pet Biopharmaceuticals Revenue by Application (2021-2026)
  8. 9.4.2 Europe Pet Biopharmaceuticals Revenue by Application (2027-2032)
  9. 9.5 Europe Pet Biopharmaceuticals Revenue Share by Application (2021-2032)
  10. 9.6 Europe Pet Biopharmaceuticals Revenue by Country
  11. 9.6.1 Europe Pet Biopharmaceuticals Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Pet Biopharmaceuticals Revenue by Country (2021-2026)
  13. 9.6.3 Europe Pet Biopharmaceuticals Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Pet Biopharmaceuticals Revenue (2021-2032)
  2. 10.2 China Pet Biopharmaceuticals Revenue by Type (2021-2032)
  3. 10.2.1 China Pet Biopharmaceuticals Revenue by Type (2021-2026)
  4. 10.2.2 China Pet Biopharmaceuticals Revenue by Type (2027-2032)
  5. 10.3 China Pet Biopharmaceuticals Revenue Share by Type (2021-2032)
  6. 10.4 China Pet Biopharmaceuticals Revenue by Application (2021-2032)
  7. 10.4.1 China Pet Biopharmaceuticals Revenue by Application (2021-2026)
  8. 10.4.2 China Pet Biopharmaceuticals Revenue by Application (2027-2032)
  9. 10.5 China Pet Biopharmaceuticals Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Pet Biopharmaceuticals Revenue (2021-2032)
  2. 11.2 Asia Pet Biopharmaceuticals Revenue by Type (2021-2032)
  3. 11.2.1 Asia Pet Biopharmaceuticals Revenue by Type (2021-2026)
  4. 11.2.2 Asia Pet Biopharmaceuticals Revenue by Type (2027-2032)
  5. 11.3 Asia Pet Biopharmaceuticals Revenue Share by Type (2021-2032)
  6. 11.4 Asia Pet Biopharmaceuticals Revenue by Application (2021-2032)
  7. 11.4.1 Asia Pet Biopharmaceuticals Revenue by Application (2021-2026)
  8. 11.4.2 Asia Pet Biopharmaceuticals Revenue by Application (2027-2032)
  9. 11.5 Asia Pet Biopharmaceuticals Revenue Share by Application (2021-2032)
  10. 11.6 Asia Pet Biopharmaceuticals Revenue by Country
  11. 11.6.1 Asia Pet Biopharmaceuticals Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Pet Biopharmaceuticals Revenue by Country (2021-2026)
  13. 11.6.3 Asia Pet Biopharmaceuticals Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Pet Biopharmaceuticals Revenue (2021-2032)
  2. 12.2 SAMEA Pet Biopharmaceuticals Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Pet Biopharmaceuticals Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Pet Biopharmaceuticals Revenue by Type (2027-2032)
  5. 12.3 SAMEA Pet Biopharmaceuticals Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Pet Biopharmaceuticals Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Pet Biopharmaceuticals Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Pet Biopharmaceuticals Revenue by Application (2027-2032)
  9. 12.5 SAMEA Pet Biopharmaceuticals Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Pet Biopharmaceuticals Revenue by Country
  11. 12.6.1 SAMEA Pet Biopharmaceuticals Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Pet Biopharmaceuticals Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Pet Biopharmaceuticals Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst